Capetero (Capecitabine)

Capetero (Capecitabine) is an oral chemotherapy medication used to treat multiple cancer types including colorectal, breast, gastric, and pancreatic cancers. As an antimetabolite prodrug, capecitabine converts to 5-fluorouracil (5-FU) within tumor tissues, providing selective cancer cell targeting with reduced systemic toxicity.

Capecitabine is indicated for adjuvant and metastatic colorectal cancer, metastatic breast cancer (particularly following anthracycline or taxane therapy failure), gastric cancer, and pancreatic cancer in combination regimens. This oral chemotherapy offers an alternative to intravenous 5-FU administration.

Contraindications include hypersensitivity to capecitabine or 5-FU, severe renal impairment (creatinine clearance below 30 mL/min), dihydropyrimidine dehydrogenase (DPD) enzyme deficiency, and use during pregnancy or breastfeeding due to teratogenic effects. DPD deficiency screening is critical as it significantly increases toxicity risk.

Dosage is determined by your oncologist based on individual factors including body surface area, renal function, and treatment protocol. Always take capecitabine exactly as prescribed. Do not initiate, modify, or discontinue this medication without explicit medical consultation and supervision by your healthcare provider, as improper use may result in serious adverse effects.

This medication is a potent chemotherapy agent requiring careful monitoring and professional medical guidance throughout treatment.